E. Laird

发表

CAMEO: a program for the logical prediction of the products of organic reactions

W. L. Jorgensen, H. Helson, E. Laird, 1990 .

Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf,and MEK

Ellen R. Laird, E. Laird, J. Lyssikatos, 2006 .

Case Studies: Selective Inhibitors of Protein Kinases – Exploiting Demure Features

E. Laird, 2015 .

Potent, selective pyrimidinetrione-based inhibitors of MMP-13.

J. Pandit, E. Laird, D. Robertson, 2006, Bioorganic & medicinal chemistry letters.

Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.

E. Laird, S. Gloor, G. Vigers, 2014, Bioorganic & medicinal chemistry letters.

The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.

J. Blake, E. Laird, M. Drew, 2007, Bioorganic & medicinal chemistry letters.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

E. Laird, Y. Ran, G. Hatzivassiliou, 2012, Journal of medicinal chemistry.

Synthesis of spirolactams and spiropiperidines as CCR4 receptor antagonists

Aaron S. Anderson, E. Laird, D. Chantry, 2006 .

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical development.

F. Lombardo, A. Kalgutkar, E. Laird, 2006, Bioorganic & medicinal chemistry letters.

Novel N-substituted 2-phenyl-1-sulfonylamino-cyclopropane carboxylates as selective ADAMTS-5 (Aggrecanase-2) inhibitors.

E. Laird, Makoto Shiozaki, J. Haas, 2009, Bioorganic & medicinal chemistry letters.

Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain.

E. Laird, B. Sahagan, J. Stock, 2002, Biochemistry.

Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.

E. Laird, L. Buckbinder, M. Wessel, 2009, Journal of medicinal chemistry.

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.

D. Danley, J. Pandit, E. Laird, 2007, Bioorganic & medicinal chemistry letters.

3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor

E. Laird, L. Melvin, M. Conklyn, 1997 .

The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Non-oxime inhibitors of B-Raf(V600E) kinase.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Computer-assisted mechanistic evaluation of organic reactions. 17. Free-radical chain reactions

William L. Jorgensen, Ellen R. Laird, W. L. Jorgensen, 1990 .

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinase.

Dennis E Danley, P. Lemotte, M. Mansour, 2005, Journal of medicinal chemistry.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Tyler Risom, Zhaoyang Wen, Ignacio Aliagas, 2011, ACS medicinal chemistry letters.

Non-oxime pyrazole based inhibitors of B-Raf kinase.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Potent and selective pyrazole-based inhibitors of B-Raf kinase.

Mike Welch, E. Laird, B. Brandhuber, 2008, Bioorganic & medicinal chemistry letters.

Computer assisted analysis of reactions involving organic free radicals and diradicals

William L. Jorgensen, Ellen R. Laird, W. L. Jorgensen, 1990, J. Chem. Inf. Comput. Sci..

Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.

Dennis E Danley, D. Danley, G. Schulte, 2002, Bioorganic & medicinal chemistry letters.

Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists.

Aaron S. Anderson, E. Laird, D. Chantry, 2004, Bioorganic & medicinal chemistry letters.

Structure-based generation of viable leads from small combinatorial libraries.

James F Blake, J. Blake, E. Laird, 2004, Current opinion in drug discovery & development.

Chppter 30. Recent advances in virtual ligand screening

Ellen R. Laird, James F. Blake, J. Blake, 2003 .

Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.

M. Hatada, E. Laird, M. Botfield, 1995, Structure.

Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor

M. Hatada, E. Laird, M. Zoller, 1995, Nature.

Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.

Masahiro Tanaka, E. Laird, Makoto Shiozaki, 2011, Journal of medicinal chemistry.

Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.

E. Laird, Makoto Shiozaki, M. Yokota, 2009, Bioorganic & medicinal chemistry letters.

Specificity determinants of human cathepsin s revealed by crystal structures of complexes.

Traian Sulea, Miroslaw Cygler, Robert Ménard, 2003, Biochemistry.

Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.

E. Laird, R. Robinson, M. Reese, 2001, Bioorganic & medicinal chemistry letters.

Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor

Ellen R. Laird, M. Hatada, E. Laird, 2007, Nature.

Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.

L. Arik, E. Laird, V. Viswanadhan, 2007, Journal of medicinal chemistry.

Monte Carlo simulations of pure liquid substituted benzenes with OPLS potential functions

William L. Jorgensen, Ellen R. Laird, Toan B. Nguyen, 1993, J. Comput. Chem..

Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.

Zhaoyang Wen, Joachim Rudolph, E. Laird, 2013, Bioorganic & medicinal chemistry letters.

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

D. Danley, J. Pandit, E. Laird, 2005, Bioorganic & medicinal chemistry letters.

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Ellen R. Laird, Tyler Risom, Zhaoyang Wen, 2011, Bioorganic & medicinal chemistry letters.

Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.

J. Blake, E. Laird, R. Robinson, 2000, Journal of medicinal chemistry.

Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.

E. Laird, S. Gloor, Jonas Grina, 2012, Bioorganic & medicinal chemistry letters.

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Ashutosh Kumar Singh, A. Drilon, K. Ching, 2023, Cancer Discovery.

Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.

E. Laird, S. Chia, V. Borges, 2011 .

5-alkyl-1,3-oxazole derivatives of 6-amino-nicotinic acids as alkyl ester bioisosteres are antagonists of the P2Y12 receptor.

E. Laird, D. Clarke, Jonas Boström, 2013, Future medicinal chemistry.

Novel N-substituted 2-phenyl-1-sulfonylamino-cyclopropane carboxylates as selective ADAMTS-5 (Aggrecanase-2) inhibitors.

E. Laird, Makoto Shiozaki, T. Miura, 2009, Bioorganic & medicinal chemistry letters.

Potent, selective pyrimidinetrione-based inhibitors of MMP-13.

J. Pandit, E. Laird, D. Robertson, 2006, Bioorganic & Medicinal Chemistry Letters.